Group 1 - The A-share innovative drug sector experienced a significant surge in the afternoon, with notable stocks such as Shutai Shen and Guanhao Bio hitting the 20% daily limit increase [1] - Nuo Si Lan De saw a substantial rise of 18%, while Warner Pharmaceuticals increased by over 17% [1] - Other companies like Ruizhi Medicine and Beilu Pharmaceutical also followed the upward trend [1]

Financial Performance - In Q1 2025, Beilu Pharmaceutical achieved operating revenue of 28,268.07 million yuan, a year-on-year increase of 36.23% [2] - The net profit attributable to shareholders increased by 26.13%, amounting to 1,308.80 million yuan, while the net profit excluding non-recurring gains and losses rose by 14.34% [2] Business Growth Drivers - The growth in Q1 2025 was primarily driven by three core segments: chemical generic drugs, traditional Chinese medicine, and overseas markets [3] - The acquisition of Tianyuan Pharmaceutical has led to significant integration efforts, enhancing marketing strategies and operational efficiency [3] Market Expansion - The company plans to leverage EU and Brazil GMP certifications to accelerate market development in these regions, aiming to enhance international brand influence and market share [4][5] - In Q1 2025, the subsidiary Haichang Pharmaceutical's iodinated contrast agent received approval for sale in South Korea, and the iodinated injection was approved in the EU [4] Financial Structure - The debt ratio reached 42.49% in Q1 2025, an increase attributed to a new long-term loan of 160 million yuan for acquiring 80% of Tianyuan Pharmaceutical [4] - Future plans include optimizing the capital structure and reducing the debt ratio through diversified financing channels [4] Subsidiary Developments - The company has established several wholly-owned subsidiaries, including: - Beijing Aipai Kesi Pharmaceutical R&D Co., focusing on product development and technological upgrades [5] - Anhui Luying Pharmaceutical Co., assisting in operations at the Bozhou production base [5] - Hong Kong Yuan Zhi Pharmaceutical Co., serving as an overseas window for market expansion [5] Product and Market Strategy - The company is actively promoting the Jiuwei Zhenxin Granules to enhance market share, despite stable procurement prices for key ingredients [5] - The company has not yet entered the veterinary medicine sector, focusing instead on prescription drugs [7]

Core Points - The document outlines the management and usage of raised funds by Beijing Beilu Pharmaceutical Co., Ltd, emphasizing compliance with relevant laws and regulations [2][3][4] - The company is required to ensure that the use of raised funds aligns with the commitments made in the prospectus and cannot change the intended use without shareholder approval [3][4][6] - The document specifies the establishment of special accounts for raised funds, which must be managed separately from other funds [4][5][6] Fund Management - The company must conduct verification of raised funds by a qualified accounting firm and disclose the status of these funds in annual reports [4][6][7] - A tripartite supervision agreement must be signed with the sponsor or independent financial advisor and the commercial bank where the funds are stored [6][7][8] - The company is required to ensure that raised funds are used for main business activities and cannot be used for high-risk investments or financial investments [9][10][11] Fund Usage - The company must follow the investment plan as stated in the issuance application and disclose any significant deviations from the plan [9][10][11] - Any changes in the use of raised funds must be approved by the board of directors and independent directors, and disclosed to shareholders [12][13][14] - The company must report on the progress of investment projects every six months and provide a special report on the use of raised funds [18][19][20] Fund Supervision - The internal audit department must check the status of raised funds at least quarterly and report findings to the board [36][37] - Independent directors can hire accounting firms to verify the use of raised funds if discrepancies are found [20][21] - Any violations in the use of raised funds that result in losses to the company will hold responsible personnel accountable [21][22]

（2025年修订） 第一章 总则 第一条 为进一步完善北京北陆药业股份有限公司（以下简称"公司"）治理结构，规 范公司总经理的工作，依照《中华人民共和国公司法》 （以下简称"《公司法》"）、 《深圳证券 交易所创业板股票上市规则》和《北京北陆药业股份有限公司章程》（以下简称"《公司章 程》"）以及国家的相关法规，特制定本细则。 第二条 公司依法设置总经理。总经理主持公司日常生产经营和管理工作，组织实施 董事会决议，对董事会负责。 第二章 总经理的任职资格与任免程序 第三条 总经理任职应当具备下列条件： （四）诚信勤勉，廉洁奉公，民主公道； （五）年富力强，有较强的使命感和积极开拓进取精神。 （一）具有较丰富的经济理论知识、管理知识及实践经验，具有较强的经营管理能力； （二）具有调动员工积极性的领导能力，建立合理的组织机构、协调各种内外关系和 统揽全局的能力； （三）具有一定年限的企业管理或经济工作经历，精通本行，熟悉多种行业的生产经 营业务和掌握国家有关政策、法律、法规； 第四条 有下列情形之一者，不得担任公司总经理： （一）无民事行为能力或者限制民事行为能力者； （二）因贪污、贿赂、侵占财产、挪用财产罪或者 ...

Core Viewpoint - The document outlines the regulations and procedures for Beijing Beilu Pharmaceutical Co., Ltd. regarding external guarantees, aiming to protect investor interests and mitigate risks associated with such guarantees [1][2]. Group 1: General Provisions - The company and its subsidiaries must manage external guarantees uniformly and require board or shareholder approval before providing any guarantees [1][2]. - External guarantees must adhere to principles of legality, prudence, mutual benefit, and safety, with strict risk control measures in place [1][2]. Group 2: Approval Authority and Conditions - The company will only provide guarantees for subsidiaries with independent legal status and sufficient repayment ability, including those under actual control or with significant business relationships [6]. - The total amount of external guarantees cannot exceed 50% of the company's net assets from the most recent audited financial statements [8]. Group 3: Risk Management and Review - The finance department is responsible for reviewing guarantee applications, assessing the creditworthiness of applicants, and ensuring that collateral is adequate [13][14]. - The board of directors must approve guarantees exceeding 10% of the latest audited net assets or total guarantees exceeding 50% of net assets [10][11]. Group 4: Information Disclosure - The company must disclose external guarantee information in accordance with relevant regulations, including details of the board or shareholder resolutions and total guarantee amounts [39][40]. - Any changes in the status of the guaranteed party that may affect repayment capabilities must be reported promptly to ensure compliance with disclosure obligations [42][43]. Group 5: Responsibilities and Penalties - All directors are responsible for managing and controlling the risks associated with external guarantees and may face liability for any violations [46][48]. - The company must establish a regular review system for guarantee activities and take corrective actions for any violations to protect shareholder interests [49][50].

Group 1 - The company is established as a joint-stock company in accordance with the Company Law and other relevant regulations [2][3] - The registered capital of the company is RMB 491,855,896 [3] - The company was approved by the China Securities Regulatory Commission to issue 17 million shares of ordinary stock to the public in 2009 [2][3] Group 2 - The company's business scope includes the production and sale of large-volume injections, small-volume injections, tablets, granules, and raw materials [4][5] - The company aims to leverage its technological advantages and high-tech talent resources to provide high-quality pharmaceutical products and services [4] Group 3 - The company has a share structure consisting of ordinary shares, with a total of 491,855,896 shares issued [8] - The shares are issued at a par value of RMB 1 per share [8] Group 4 - The company’s shareholders have the right to receive dividends and participate in decision-making processes at the shareholders' meetings [12][13] - Shareholders holding more than 5% of the shares are subject to specific trading restrictions [10][11] Group 5 - The company’s board of directors is responsible for major decisions, and shareholders have the right to request the convening of shareholder meetings under certain conditions [20][23] - The company must disclose information regarding significant transactions and decisions to ensure transparency [42][43]

（二）由前项所述法人（或者其他组织）直接或间接控制的除公司及其控股子公司以 外的法人（或者其他组织）； （三）持有公司5%以上股份的法人（或者其他组织）及其一致行动人； （2025年修订） 第一章 总则 第一条 为规范北京北陆药业股份有限公司（以下简称"公司"）的关联交易行为，保 证公司与关联方之间的关联交易符合公平、公正、公开的原则，确保公司的关联交易行为 不损害公司和全体股东的合法权益，根据《中华人民共和国公司法》、《中华人民共和国证 券法》、《深圳证券交易所创业板股票上市规则》（以下简称"《创业板上市规则》"）、 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等有关法律、 法规、规范性文件和《北京北陆药业股份有限公司章程》（以下简称"《公司章程》"）的 有关规定，制订本办法。 第二条 公司与关联方之间的关联交易行为除遵守有关法律、法规、规范性文件和《公 司章程》的规定外，还需遵守本办法的相关规定。 第二章 关联人和关联关系的确认 第三条 公司关联人包括关联法人（或者其他组织）和关联自然人。除遵循有关法律、 法规、规范性文件和《公司章程》外，公司董事会对关联关系从实质进行判断，遵循 ...

Core Points - The document outlines the investment management system of Beijing Beilu Pharmaceutical Co., Ltd, aiming to standardize external investment behavior and ensure scientific decision-making [1][2] - The investment policy emphasizes compliance with national industrial policies, safety of funds, and prioritization of benefits [1][2] - The investment management structure includes decision-making bodies such as the shareholders' meeting, board of directors, and general manager's office [2][3] Investment Scope - The types of investments covered include independent business establishment, fixed asset investments, financial management, and joint ventures [1][2] - Investments do not include guarantees and related party transactions [2] Decision-Making Authority - Investments involving assets exceeding 30% of the company's audited total assets require shareholders' meeting approval [3][4] - The board of directors can approve investments outside the shareholders' meeting authority, while the general manager can approve transactions below 2 million yuan [4] Investment Management Process - Investment projects must align with national development directions and undergo thorough feasibility studies [5][6] - The project management process includes planning, financial management, and progress reporting to the general manager [5][6] Collaboration with Professional Investment Institutions - The company can establish investment funds with professional institutions and must disclose relevant information regarding these collaborations [6][7] - Any joint investments must be disclosed promptly, including the maximum potential loss [7][8] Investment Transfer and Recovery - The company can recover investments under specific circumstances, such as project completion or bankruptcy [10] - Investment transfers must comply with legal regulations and company policies [10] Rewards and Penalties - Successful investment projects may lead to rewards for responsible personnel [11] - Penalties are outlined for individuals who cause significant losses through negligence or misconduct [12][13]

（2025年修订） 第一章 总 则 （五）个人所负数额较大的债务到期未清偿被人民法院列为失信被执行人； （六）最近三十六个月内受到中国证监会行政处罚； （七）最近三十六个月内受到证券交易所公开谴责或三次以上通报批评； 第二条 公司董事会对股东会负责，并依据国家有关法律、法规和《公司章程》行使职 权。 第二章 董事的资格及任职 第三条 公司董事为自然人，有下列情形之一的，不能担任公司的董事，其中独立董事 的任职资格另有规定的，从其规定。 （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩序，被判处刑 罚，或者因犯罪被剥夺政治权利，执行期满未逾五年，被宣告缓刑的，自缓刑考验期满之 日起未逾二年； 第一条 为规范北京北陆药业股份有限公司（以下简称"公司"）董事会的工作秩序和 行为方式，保证公司董事会依法行使权利、履行职责、承担义务，根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）颁布的《上市公司治理准则》（以下 简称"《治理准则》"）、《深圳证券交 ...

（2025年修订） 第三条 本工作制度所称的高级管理人员是指公司的总经理、常务副总经理、副总经 理、首席运营官、财务负责人、董事会秘书。 第二章 人员组成 第四条 提名委员会成员由三名董事组成，其中独立董事两名。 第五条 提名委员会委员由董事长、二分之一以上独立董事或者全体董事三分之一以 上提名，由董事会选举产生。 第六条 提名委员会设主任委员一名，负责主持委员会工作。主任委员由独立董事委 员担任，并经全体委员过半数选举产生。 第七条 提名委员会任期与董事会一致，委员任期届满，可以连选连任。期间如有委 员不再担任公司董事职务，自动失去委员资格，并由董事会根据上述第四至第六条规定补 足委员人数。 第一章 总则 第一条 为规范北京北陆药业股份有限公司（以下简称"公司"）董事和高级管理人 员的产生，优化董事会组成，进一步完善公司治理结构，根据《中华人民共和国公司法》、 《上市公司治理准则》、《北京北陆药业股份有限公司章程》（以下简称"《公司章程》"） 及其他有关规定，公司董事会特设立提名委员会（以下简称"提名委员会"），并制定本工 作制度。 第二条 提名委员会是董事会设立的专门工作机构，主要负责对公司董事和高级管理 ...